中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.02 seconds)

    N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors
    4.
    发明申请
    N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors 有权
    N1-Pyrazolospiroketone乙酰辅酶A羧化酶抑制剂

    公开(公告)号：US20130030181A1

    公开(公告)日：2013-01-31

    申请号：US13644415

    申请日：2012-10-04

    Applicant: Pfizer Inc.

    Inventor： Scott William Bagley ,  David Andrew Griffith ,  Daniel Wei-Shung Kung

    IPC: C07D471/10

    CPC classification number: C07D471/10 ,  C07D519/00

    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

    Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。

    N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
    7.
    发明授权
    N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors 有权
    N-吡唑啉酮酮乙酰辅酶A羧化酶抑制剂

    公开(公告)号：US09139587B2

    公开(公告)日：2015-09-22

    申请号：US14273912

    申请日：2014-05-09

    Applicant: Pfizer Inc.

    Inventor： Scott William Bagley ,  David Andrew Griffith ,  Daniel Wei-Shung Kung

    IPC: C07D471/10 ,  C07D519/00

    CPC classification number: C07D471/10 ,  C07D519/00

    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

    Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。

    N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
    8.
    发明授权
    N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors 有权
    N-吡唑啉酮酮乙酰辅酶A羧化酶抑制剂

    公开(公告)号：US08802690B2

    公开(公告)日：2014-08-12

    申请号：US13939450

    申请日：2013-07-11

    Applicant: Pfizer Inc.

    Inventor： Scott William Bagley ,  David Andrew Griffith ,  Daniel Wei-Shung Kung

    IPC: C07D487/10 ,  A61K31/438

    CPC classification number: C07D471/10 ,  C07D519/00

    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

    Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4如本文所述; 其药物组合物; 以及其用于治疗通过抑制动物体内的乙酰辅酶A羧化酶调节的疾病，病症或病症的用途。

    NOVEL ACC INHIBITORS
    9.
    发明公开
    NOVEL ACC INHIBITORS 审中-公开

    公开(公告)号：US20240109915A1

    公开(公告)日：2024-04-04

    申请号：US18359709

    申请日：2023-07-26

    Applicant: Pfizer Inc.

    Inventor： Scott William Bagley ,  Andrea Nicole Bootsma ,  Chulho Choi ,  Robert Lee Dow ,  David James Edmonds ,  Carmen Noemi Garcia-Irizarry ,  Brian Stephen Gerstenberger ,  Gajendra Ingle ,  Jessica Gloria Katherine O'Brien ,  Mihir Dineshkumar Parikh ,  Gwenaella Christine Rescourio ,  Daniel Copley Schmitt

    IPC: C07D513/10

    CPC classification number: C07D513/10

    Abstract: A compound having the structures:




    or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein; R selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy and —(CH2)m—W, where W is C3-C8 cycloalkyl, bicycloalkyl, bridged bicycloalkyl, phenyl, 5- or 6-membered heteroaryl or heterocyclic containing one, two or three heteroatoms selected from the group consisting of N, S and O atoms; wherein each of said alkyl, cycloalkyl, alkoxy, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, halo, cyano, deuterium, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, —SO2—R′, —CONR′R″, NR′COR″, —NR′CONR′R″, —NR′CO2R″, —(CH2)n—SO2—R′, —NHSO2—R′, —NR″SO2—R′, —SO2NR′R″, NR′R″ or SR′ where R′ and R″ are independently H, C1-C6 alkyl or C3-C8 cycloalkyl; R1 selected from the group consisting of phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing one, two, three or four heteroatoms selected from the group consisting of N, S and O atoms; and, a 9- or 10-membered bicyclic aryl, heteroaryl or heterocyclic containing one, two or three heteroatoms selected from the group consisting of N, S and O atoms; wherein each of said phenyl, naphthyl, aryl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, deuterium, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, phenyl, —SO2—R′, —CONR′R″, NR′COR″, —NR′CONR′R″, —NR′CO2R″, —(CH2)n—SO2—R′, —NHSO2—R′, —NR″SO2—R, —SO2NR′R″, —P(O)R′R″,




    or NR′R″′ or SR′ where R′ and R″ are independently H, C1-C6 alkyl or C3-C8 cycloalkyl; and, m and n are independently 0, 1, 2 or 3. The invention also relates to pharmaceutically acceptable salts of these compounds and to pharmaceutically acceptable solvates thereof; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly acne.

Patent Agency Ranking